Monte Rosa Therapeutics, Inc.GLUEEarnings & Financial Report
Nasdaq
NextMar 20, 2026
GLUE Q3 2025 Key Financial Metrics
Revenue
$12.8M
Gross Profit
N/A
Operating Profit
$-33.0M
Net Profit
$-27.1M
Gross Margin
N/A
Operating Margin
-258.3%
Net Margin
-212.1%
YoY Growth
38.5%
Financial Flow
Monte Rosa Therapeutics, Inc. Q3 2025 Financial Summary
Monte Rosa Therapeutics, Inc. reported revenue of $12.8M for Q3 2025, with a net profit of $-27.1M (-212.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $12.8M |
|---|---|
| Net Profit | $-27.1M |
| Gross Margin | N/A |
| Operating Margin | -258.3% |
| Report Period | Q3 2025 |
Monte Rosa Therapeutics, Inc. Annual Revenue by Year
Monte Rosa Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $75.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $75.6M |
| 2023 | $0 |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.1M | $4.7M | $9.2M | $60.6M | $84.9M | $23.2M | $12.8M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 7882.0% | 394.0% | 38.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $303.8M | $266.7M | $344.1M | $315.1M | $438.7M | $393.2M | $359.6M | $459.8M |
| Liabilities | $124.5M | $114.2M | $119.4M | $109.6M | $215.8M | $118.0M | $91.5M | $214.0M |
| Equity | $179.3M | $152.5M | $224.7M | $205.5M | $222.9M | $275.2M | $268.1M | $245.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $29.6M | $-38.2M | $-27.8M | $-21.0M | $128.9M | $-45.5M | $-34.7M | $100.4M |